Coherus Bio (CHRS) Stock Price, Quote & News

Company Profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investi...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 649 3530

Website: www.coherus.com

Address:

333 Twin Dolphin Drive, Suite 600, Redwood City, United States

Sven_Bonn Sep. 1 at 12:50 AM

$CHRS the path couldn’t be clearer

1 · Reply

whateverhappenedthere Sep. 1 at 12:11 AM

$CHRS me on any CHRS down day from here on out

1 · Reply

simonig1 Aug. 31 at 8:46 PM

$CHRS Link: https://x.com/kurtsaltrichter/status/2094154446901014772

0 · Reply

Samishere Aug. 31 at 8:12 PM

$CHRS Just my 2 cents ,, but your fellow bags will be needing your expertise very soon ,, So get back to work at the …

1 · Reply

Samisphere_TRUTH Aug. 31 at 7:16 PM

$CHRS scammer John aka Toadvind aka Chadlawton can't help doing his daily job of paid botting. Promises will be kept. Stocktwits is nice but reddit needs to know more about your scams.

0 · Reply

calibran_de Aug. 31 at 6:25 PM

$CHRS Rough day today!

0 · Reply

Grandgustav Aug. 31 at 4:17 PM

$CHRS just my two cents: I think the offering is an insurance policy that may or may not be executed. if a buyout is coming, they likely won’t dilute more, but like Paulie said, we always have the option. Secondly, i think we get casdo data a day before the first presentation. Denny wants to be there with great results to tout. just my estimation

2 · Reply

Samishere Aug. 31 at 3:16 PM

$CHRS Only down ANOTHER 7% today Shorts must be covering in droves!

1 · Reply

Samishere Aug. 31 at 2:24 PM

$CHRS Wow! You beat up bags are right ! Shorts are scared shitless from the CVR divy!! Look at them all cover ! LMFAO!! Again ! I bet even more shorts cover after the up coming “ investor conference “ Not! 🤣🤪🤣🤪🤣🤪🤣

0 · Reply

Samishere Aug. 31 at 2:17 PM

$CHRS Hope does spring eternal,, but it’s a horrible investment strategy! Big Data release? This ER? Next ER? Frightened shorts covering? Buy Out coming? …Now its an investor conference that will seize the day ? Good gawd you pumping bags are thick! 🤣🤪🤣🤪🤪🤣🤣

0 · Reply

Coherus to Participate in Upcoming Investor Conferences

2026-08-17T21:40:09.000Z - 14 days ago

Coherus Oncology issuing special dividend of biosimilar contingent value rights

Aug 17, 2026, 5:33 PM EDT - 14 days ago

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

2026-08-07T11:46:55.000Z - 24 days ago

Coherus Oncology price target lowered to $10 from $12 at Guggenheim

2026-08-05T22:40:15.000Z - 26 days ago

Coherus Oncology reports Q2 EPS (19c), consensus (12c)

Aug 5, 2026, 5:00 PM EDT - 26 days ago

Coherus Oncology Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 26 days ago

Coherus Oncology Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 26 days ago

Coherus Oncology Quarterly report: Q2 2026

Aug 5, 2026, 4:28 PM EDT - 26 days ago

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Jul 22, 2026, 1:36 PM EDT - 5 weeks ago

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

2026-06-23T19:19:59.000Z - 2 months ago

Coherus, Zumutor collaborate for ZM008, Loqtorzi combination study

Jun 23, 2026, 2:00 PM EDT - 2 months ago

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

Jun 4, 2026, 9:55 AM EDT - 3 months ago

Coherus Oncology Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 8:00 AM EDT - 3 months ago

Coherus Oncology Proxy statement: Proxy filing

May 27, 2026, 4:30 PM EDT - 3 months ago

Coherus Oncology Transcript: AGM 2026

2026-05-11T23:20:35.000Z - 4 months ago

Coherus Oncology reports Q1 EPS (28c), consensus (26c)

May 11, 2026, 5:00 PM EDT - 4 months ago

Coherus Oncology Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

Coherus Oncology Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

Coherus Oncology Quarterly report: Q1 2026

May 11, 2026, 4:05 PM EDT - 4 months ago

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

2026-05-11T12:37:08.000Z - 4 months ago

Guggenheim starts Coherus with Buy on anti-tumor potential

2026-05-11T10:36:08.000Z - 4 months ago

Coherus Oncology initiated with a Buy at Guggenheim

May 5, 2026, 8:00 AM EDT - 4 months ago

Coherus Oncology Proxy statement: Proxy filing

May 4, 2026, 9:30 AM EDT - 4 months ago

Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Coherus Oncology Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Coherus Oncology Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 5 months ago

Coherus Oncology Proxy statement: Proxy filing

Mar 10, 2026, 2:50 PM EDT - 6 months ago

Coherus Oncology Transcript: The Citizens Life Sciences Conference 2026

2026-03-09T20:40:57.000Z - 6 months ago

Coherus Oncology reports Q4 EPS (34c), consensus (31c)

Mar 9, 2026, 4:30 PM EDT - 6 months ago

Coherus Oncology Earnings Call Transcript: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 6 months ago

Coherus Oncology Annual report: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 6 months ago

Coherus Oncology Earnings release: Q4 2025

Mar 9, 2026, 4:15 PM EDT - 6 months ago

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

Mar 4, 2026, 11:50 AM EST - 6 months ago

Coherus Oncology Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:30 AM EST - 6 months ago

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

Feb 23, 2026, 9:30 AM EST - 6 months ago

Coherus Oncology to Participate in Upcoming Investor Conferences

Feb 17, 2026, 4:11 PM EST - 6 months ago

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

2026-02-13T11:50:56.000Z - 7 months ago

Coherus Oncology 28.6M share Spot Secondary priced at $1.75

Feb 12, 2026, 9:18 PM EST - 7 months ago

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

2026-02-12T21:12:06.000Z - 7 months ago

Coherus Oncology announces common stock offering, no amount given

2026-01-22T21:16:58.000Z - 7 months ago

Coherus Oncology initiated with an Outperform at Oppenheimer ahead of readouts

2026-01-22T21:11:03.000Z - 7 months ago

Coherus Oncology initiated with an Outperform at Oppenheimer

Jan 13, 2026, 1:30 PM EST - 8 months ago

Coherus Oncology Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 1:30 PM EST - 8 months ago

Coherus Oncology Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 9:30 AM EST - 8 months ago

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

2026-01-05T14:51:47.000Z - 8 months ago

Coherus Oncology announces publication highlighting CCR8 antibody tagmokitug

Jan 5, 2026, 9:30 AM EST - 8 months ago

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

Dec 17, 2025, 1:30 PM EST - 9 months ago

Coherus Oncology Transcript: Biotech Discovery Series

2025-12-08T13:45:59.000Z - 9 months ago

Coherus Oncology announces six-year OS results from Phase 3 JUPITER-02 trial

Dec 8, 2025, 8:30 AM EST - 9 months ago

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Nov 18, 2025, 5:30 AM EST - 10 months ago

Coherus Oncology Transcript: Jefferies London Healthcare Conference 2025

2025-11-13T22:35:29.000Z - 10 months ago

Coherus Oncology files $150M mixed securities shelf

Nov 13, 2025, 7:00 AM EST - 10 months ago

Coherus Oncology Registration statement: Registration Filing

Nov 10, 2025, 1:15 PM EST - 10 months ago

Coherus Oncology Transcript: UBS Global Healthcare Conference 2025

Nov 7, 2025, 9:00 AM EST - 10 months ago

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Nov 6, 2025, 5:00 PM EST - 10 months ago

Coherus Oncology Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

Coherus Oncology Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

Coherus Oncology Earnings release: Q3 2025

Nov 6, 2025, 4:14 PM EST - 10 months ago

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 1:54 PM EST - 10 months ago

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Oct 30, 2025, 8:30 AM EDT - 10 months ago

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 3, 2025, 9:05 AM EDT - 11 months ago

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 1, 2025, 1:00 PM EDT - 11 months ago

Coherus Oncology Transcript: UBS Virtual Oncology Day

Sep 10, 2025, 11:00 AM EDT - 1 year ago

Coherus Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 1:25 PM EDT - 1 year ago

Coherus Oncology Transcript: Baird Global Healthcare Conference 2025

2025-09-04T11:35:24.000Z - 1 year ago

Coherus Biosciences upgraded to Buy from Neutral at Roth Capital

2025-09-04T11:35:13.000Z - 1 year ago

Coherus Biosciences upgraded to Buy from Hold at Maxim

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings release: Q2 2025

Aug 7, 2025, 4:41 PM EDT - 1 year ago

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 4:45 PM EDT - 1 year ago

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Coherus Oncology Slides: Corporate Presentation

Jun 4, 2025, 5:30 PM EDT - 1 year ago

Coherus Oncology Transcript: Jefferies Global Healthcare Conference 2025

May 27, 2025, 3:00 PM EDT - 1 year ago

Coherus Oncology Transcript: 6th Annual Oncology Innovation Summit

May 20, 2025, 12:00 PM EDT - 1 year ago

Coherus Oncology Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings Call Transcript: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Quarterly report: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings release: Q1 2025

May 12, 2025, 4:15 PM EDT - 1 year ago

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 9:00 AM EDT - 1 year ago

Coherus Oncology Transcript: The Citizens JMP Life Sciences Conference 2025

May 5, 2025, 4:01 PM EDT - 1 year ago

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Coherus Oncology Transcript: KOL Event

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Coherus Oncology Press release: KOL Event

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Coherus Oncology Slides: KOL Event

Apr 28, 2025, 10:10 AM EDT - 1 year ago

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 10, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings Call Transcript: Q4 2024

Mar 10, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Annual report: Q4 2024

Mar 10, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings release: Q4 2024

Mar 10, 2025, 4:12 PM EDT - 1 year ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 11:50 AM EST - 1 year ago

Coherus Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Mar 3, 2025, 8:30 AM EST - 1 year ago

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Feb 24, 2025, 9:08 AM EST - 1 year ago

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 28, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 14, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 14, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 13, 2025, 8:15 PM EST - 1 year ago

Coherus Oncology Transcript: at 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 8:15 PM EST - 1 year ago

Coherus Oncology Slides: FY 2025

Dec 18, 2024, 8:30 AM EST - 1 year ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Dec 4, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Dec 4, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Dec 3, 2024, 3:15 PM EST - 1 year ago

Coherus Oncology Transcript: Citi's 2024 Global Healthcare Conference

Dec 3, 2024, 8:00 AM EST - 1 year ago

Coherus Oncology Transcript: Status Update

Dec 3, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Dec 3, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Nov 27, 2024, 4:01 PM EST - 1 year ago

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Nov 6, 2024, 5:00 PM EST - 1 year ago

Coherus Oncology Earnings Call Transcript: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Coherus Oncology Quarterly report: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Coherus Oncology Earnings release: Q3 2024

Nov 6, 2024, 4:01 PM EST - 1 year ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 4:20 PM EDT - 1 year ago

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings Call Transcript: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Quarterly report: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings release: Q2 2024

Aug 1, 2024, 9:00 AM EDT - 2 years ago

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Jun 27, 2024, 8:26 AM EDT - 2 years ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Jun 6, 2024, 8:30 AM EDT - 2 years ago

Coherus Oncology Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 9:00 AM EDT - 2 years ago

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

May 29, 2024, 12:00 PM EDT - 2 years ago

Coherus Oncology Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 23, 2024, 5:51 PM EDT - 2 years ago

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 9:00 AM EDT - 2 years ago

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

May 13, 2024, 8:00 AM EDT - 2 years ago

Coherus Oncology Proxy statement: Proxy Filing

May 9, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings Call Transcript: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Quarterly report: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings release: Q1 2024

May 9, 2024, 4:01 PM EDT - 2 years ago

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 7:30 AM EDT - 2 years ago

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

May 8, 2024, 9:00 AM EDT - 2 years ago

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

May 1, 2024, 4:30 PM EDT - 2 years ago

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 24, 2024, 10:02 AM EDT - 2 years ago

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 8, 2024, 8:30 AM EDT - 2 years ago

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Mar 13, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings Call Transcript: Q4 2023

Mar 13, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Annual report: Q4 2023

Mar 13, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings release: Q4 2023

Mar 13, 2024, 4:01 PM EDT - 2 years ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

Mar 5, 2024, 4:01 PM EST - 2 years ago

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Mar 4, 2024, 1:00 AM EST - 2 years ago

Coherus Completes Divestiture of Ophthalmology Franchise

Feb 23, 2024, 5:33 PM EST - 2 years ago

Coherus BioSciences Announces New Employment Inducement Grants

Feb 21, 2024, 8:30 AM EST - 2 years ago

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Sven_Bonn Sep. 1 at 12:50 AM

$CHRS the path couldn’t be clearer

1 · Reply

whateverhappenedthere Sep. 1 at 12:11 AM

$CHRS me on any CHRS down day from here on out

1 · Reply

simonig1 Aug. 31 at 8:46 PM

$CHRS Link: https://x.com/kurtsaltrichter/status/2094154446901014772

0 · Reply

Samishere Aug. 31 at 8:12 PM

$CHRS Just my 2 cents ,, but your fellow bags will be needing your expertise very soon ,, So get back to work at the …

1 · Reply

Samisphere_TRUTH Aug. 31 at 7:16 PM

$CHRS scammer John aka Toadvind aka Chadlawton can't help doing his daily job of paid botting. Promises will be kept. Stocktwits is nice but reddit needs to know more about your scams.

0 · Reply

calibran_de Aug. 31 at 6:25 PM

$CHRS Rough day today!

0 · Reply

Grandgustav Aug. 31 at 4:17 PM

2 · Reply

Samishere Aug. 31 at 3:16 PM

$CHRS Only down ANOTHER 7% today Shorts must be covering in droves!

1 · Reply

Samishere Aug. 31 at 2:24 PM

0 · Reply

Samishere Aug. 31 at 2:17 PM

0 · Reply

focafoca99 Aug. 31 at 2:08 PM

$CHRS looks ahead to upcoming investor conferences on Sept. 15-16, including Baird, H.C. Wainwright and Morgan Stanley events.

1 · Reply

Toadvind Aug. 31 at 2:07 PM

$CHRS

1 · Reply

Samishere Aug. 31 at 2:04 PM

$CHRS To lie to you ignorant fools -AGAIN! Literally everything that comes out of Denny’s mouth,,,,,

0 · Reply

John1066 Aug. 31 at 1:54 PM

$CHRS chat gpt has an interesting take on why 3 conferences in quick succession:

2 · Reply

John1066 Aug. 31 at 1:42 PM

$CHRS okay, so if you’re a company about to announce poor data why would you line up 3 events/presentations? 🤔

3 · Reply

RealBRand Aug. 31 at 1:33 PM

$CHRS

1 · Reply

Samisphere_TRUTH Aug. 31 at 1:04 PM

$CHRS scammers here post under all these fake accounts! It's a single scammer whose accounts posted sell sell sell at every lows. I got my bot alarms on and will spam every board they go so no one is tricked by them. Everyone will know chadlawton is bigdaddy is samisphere is tonne is the SAME SCAMMER

0 · Reply

Henry20feb_ Aug. 31 at 6:59 AM

$CHRS How much is that doggie in the window? (Arf arf) The one with the waggly tail How much is that doggie in the window? (Arf arf) I do hope that doggie's for sale I must take a trip to California And leave my poor sweetheart alone If he has a dog, he won't be lonesome And the doggie will have a good home

0 · Reply

Samishere Aug. 30 at 4:21 PM

$CHRS WOW! Jack_Ass has become a complete psychopath now! He’s even created a new handle,, in my honor! Thanks you weirdo! No, we are not bots dipshit, just rational people who know what a complete lying cockroach Denny is ,,,, and now you too! Get help, get back on your meds you lunatic!

3 · Reply

Grandgustav Aug. 30 at 3:44 PM

$CHRS

0 · Reply

Samisphere_TRUTH Aug. 29 at 4:27 PM

$CHRS if the troll bot, CHADLAWTON AKA SAMISPHERE AKA BIGDADDY AKA JOHN AKA CALI_DE AKA TOADVIND keep posting bot comments again, I will post 2x on reddit for every bot post. I will have a custom graphic with all your handles with BOT TROLL. Lowdog here is Chadlawton.

1 · Reply

Samisphere_TRUTH Aug. 29 at 12:48 PM

$CHRS why is chadlawton aka bigdaddy aka toadvind aka Sami posting the same messages here and on reddit with different handles? 😂😂😂 BOTSSSS

0 · Reply

Market Cap	90.31M
Revenue (ttm)	266.96M
Net Income (ttm)	28.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	10.68%
Debt to Equity Ratio	-0.20

Volume	1,822,400
Avg Vol	1,708,078
Day's Range	N/A - N/A
Shares Out	115.93M
Stochastic %K	30%
Beta	1.01
Analysts	Strong Sell
Price Target	$5.26